Navigation Links
China Nepstar Chain Drugstore Ltd. Reports First Quarter 2013 Financial Results

SHENZHEN, China, May 28, 2013 /PRNewswire-FirstCall/ -- China Nepstar Chain Drugstore Ltd. (NYSE: NPD) ("Nepstar" or the "Company"), the largest retail drugstore chain in China based on the number of directly operated stores, today announced its unaudited financial results for the first quarter ended March 31, 2013.

Financial HighlightsFor the quarter ended March 31, 2013:

  • Same store sales increased by 6.1% compared with the first quarter of 2012
  • Revenue increased to RMB627.4 million (US$101.0 million) from RMB625.8 million in the first quarter of 2012
  • Net income increased slightly to RMB7.1million (US$1.1 million) from RMB7.0 million in the first quarter of 2012
  • Basic and diluted earnings per American depositary share ("ADS") were RMB0.07 (US$0.01), the same as in the first quarter of 2012
  • "We are pleased to see continuing same store sales growth in the first quarter of 2013, compared with the same period of 2012," Mr. Fuxiang Zhang, Chief Executive Officer, commented. "Our focus on increasing store efficiencies and maximizing customer transactions per visit, enabled the Company to maintain top line growth momentum, even given a lower store count. In the current competitive market environment, we strive to broaden and optimize our product portfolio. We believe that our dedication to product line development and optimization has provided a solid foundation for the company to stabilize its gross margins over time."

    First Quarter ResultsDuring the first quarter of 2013, the Company opened 25 new stores and closed 63 stores. As of March 31, 2013, the Company had 2,094 directly operated stores in total.  

    Revenue for the first quarter of 2013 increased by 0.2% to RMB627.4 million (US$101.0 million) from RMB625.8 million for the same period in 2012. Same store sales (for the 2,015 stores opened before December 31, 2011 and which were still operating) for the first quarter of 2013, increased by 6.1% compared with the same period in 2012. The increase in same store sales was primarily due to promotional initiatives aimed at increasing transactions per store.

    First quarter revenue analysed by product group comprised 22.1% by sales of prescription drugs; 40.0% by over-the-counter ("OTC") drugs; 14.9% by nutritional supplements; 4.1% by herbal products; and 18.9% from convenience and other products.

    First quarter gross profit was RMB290.9 million (US$46.8 million), which was slightly decreased from RMB291.6 million in the same period of 2012. Gross margins in the first quarter of 2013 were 46.4%, compared with 46.6% in the same period of 2012. The small year-over-year decrease in gross margin was mainly the result of mandatory price cuts on certain pharmaceuticals imposed by the Chinese government together with changes in product mix, as the Company introduced more convenience products with lower gross margins.

    The Company's portfolio of private label products extended to 2,024 types of products as of March 31, 2013. Sales of private label products represented approximately 24.5% of the Company revenue and 33.9% of the gross profit for the first quarter of 2013.

    Sales, marketing and other operating expenses, as a percentage of revenue, in the first quarter of 2013 decreased to 40.2% from 40.4% in the same period of 2012. The year-over-year decrease was primarily due to the growth in same store sales and closure of underperforming stores.  

    General and administrative expenses, as a percentage of revenue, in the first quarter of 2013 was 4.4%, compared with 4.8% for the same period of 2012. The decrease was mainly due to the continued implementation of the Company's overall cost management measures.

    Income from operations in the first quarter of 2013 increased by 30.3% to RMB11.3 million (US$1.8 million) from RMB8.7 million in the same period of 2012.

    Interest income for the first quarter of 2013 was RMB4.1 million (US$0.7 million), compared with RMB5.4 million in the same period of 2012. Interest income decreased as a result of reduced cash balances following the distribution of a special dividend in the second quarter of 2012.

    Dividend income from cost method investments was RMB1.8 million (US$0.3 million) in the first quarter of 2013, compared with RMB1.4 million in the same period of 2012. Equity in income of an equity method investee was nil in the first quarter of 2013, compared with the income of RMB0.7 million in the same period of 2012. On December 28, 2012, the Company completed the sales of its entire 40% equity interests in Yunnan Jianzhijia Chain Drugstore Ltd. for a total cash consideration of approximately RMB 81.5 million.

    The Company's effective tax rate was 58.6% for the first quarter of 2013, compared with 56.8% for the same period in 2012. The higher effective tax rate for the first quarter of 2013 was caused by non-deductible expenses and the effect of operating losses from loss-making subsidiaries, for which full valuation allowances were made on their deferred tax assets.

    Net income in the first quarter of 2013 was RMB 7.1 million (US$1.1 million), which represented RMB0.07 (US$0.01) basic and diluted earnings per ADS. Net income in the first quarter of 2012 was RMB7.0 million, which also represented RMB0.07 basic and diluted earnings per ADS.

    In the first quarter of 2013, net cash-flows from operating activities were RMB6.9 million (US$1.1 million), compared with RMB0.9 million in the same period of 2012.

    As of March 31, 2013, the Company's total cash, cash equivalents, bank deposits and restricted cash were RMB662.1 million (US$106.6 million) and its shareholders' equity was RMB1.03 billion (US$166.3 million), compared with total cash, cash equivalents, bank deposits and restricted cash of RMB664.4 million and shareholders' equity of RMB1.03 billion as of December 31, 2012.

    Business Outlook"The ongoing avian flu epidemic in the second quarter of 2013 has clearly caused more visits of customers to the Company drugstores for preventive medications. Fever reducing and detoxicating drugs in our pharmaceutical category contributed to be the strong growth category in same store sales, in second quarter-to-date as compared with the same period in 2012," Mr. Zhang remarked. "We continue to execute our strategy of focusing on store productivity and cost control."

    Conference Call InformationThe Company will host a conference call and a simultaneous webcast, on Tuesday, May 28, 2013 at 8:00 a.m. Eastern Time / 8:00 p.m. Beijing Time. Interested parties may participate in the conference call by dialing in approximately five minutes before the call start time at +1-877-407-9210 (North America) or +1-201-689-8049 (International). A live webcast of the conference call will be available on the Company's website at

    A replay of the call will be available shortly after the conclusion of the event through 11:59 p.m. Eastern Time on June 4, 2013. An archived webcast of the conference call will be available on the Company's website at Interested parties may access the replay by dialing +1-877-660-6853 (North America) or +1-201-612-7415 (International) and entering conference ID number 414282.

    About China Nepstar Chain Drugstore Ltd.China Nepstar Chain Drugstore Ltd. (NYSE: NPD) is the largest retail drugstore chain in China based on the number of directly operated stores. As of March 31, 2013, the Company had 2,094 stores across 76 cities, one headquarter distribution center and 16 regional distribution centers in China. Nepstar uses directly operated stores, centralized procurement and a network of distribution centers to provide its customers with high-quality, professional and convenient pharmaceutical products and services and a wide variety of other merchandise, including OTC drugs, nutritional supplements, herbal products, personal care products, family care products, and convenience products. Nepstar's strategy of centralized procurement, competitive pricing, customer loyalty programs and private label offerings has enabled it to capitalize on the continuing economic growth in China and take advantage of the demographic trend in China to achieve a strong brand and leading market position. For further information, please go to

    Safe Harbor StatementThis press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the quotations from management in this press release and the Company's strategic operational plans and business outlook, contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

    Exchange Rate InformationThe United States dollar (US$) amounts disclosed in this press release are presented solely for the convenience of the reader. Translations of amounts from RMB into United States dollars were calculated at the certified exchange rate of US$1.00 = RMB6.2108 on March 29, 2013 as set forth in the H.10 weekly statistical release of the Federal Reserve Board. No representation is made that the RMB amounts could have been, or could be, converted into US$ at that rate on March 29, 2013, or at any other date. The percentages stated are calculated based on RMB amounts.

    ContactsZixin Shao
    China Nepstar Chain Drugstore Ltd.
    Chief Financial Officer

    Dixon Chen
    Investor Relations

    Ivette Almeida
    Media Relations

    (Tables Follow) China Nepstar Chain Drugstore Ltd. Unaudited Condensed Consolidated Statements of Comprehensive Income(amounts in thousands – except per-share data)Three-month period endedMarch 31,201220132013RMBRMBUSDRevenue

    625,835627,360101,011Cost of goods sold

    (334,257)(336,437)(54,170)Gross profit

    291,578290,92346,841Sales, marketing and other operating expenses

    (252,682)(252,085)(40,588)General and administrative expenses

    (30,239)(27,557)(4,437)Income from operations

    8,65711,2811,816Interest income

    5,3844,113662Dividend income from cost method investments

    1,4041,797289Equity in income of an equity method investee

    742--Income before income tax expense

    16,18717,1912,767Income tax expense

    (9,201)(10,077)(1,622)Net income

    6,9867,1141,145Basic earnings per ordinary share

    0.0350.0360.006Basic earnings per ADS

    0.0700.0720.012Diluted earnings per ordinary share

    0.0350.0360.006Diluted earnings per ADS

    0.0700.0720.012Other comprehensive income, net of tax:Foreign currency translation adjustments

    26(137)(22)Comprehensive income attributable to China
    Nepstar Chain Drugstore Ltd.

    7,0126,9771,123  China Nepstar Chain Drugstore Ltd.Unaudited Condensed Consolidated Balance Sheets(amounts in thousands) As ofAs ofAs ofDecember 31,March 31,March 31,201220132013RMBRMBUSDASSETSCurrent assetsCash and cash equivalents

    371,256374,03460,223Short-term bank time deposits

    237,100232,10037,370Restricted cash

    36,00036,0005,796Accounts receivable, net of allowance for doubtful

    114,601117,98618,997Amounts due from related parties

    8,2549,7601,571Prepaid expenses, deposits and other current assets


    478,483456,81673,552Deferred tax assets

    1,7043,556573Total current assets

    1,394,6501,369,292220,470Non-current assetsLong-term bank time deposits

    20,00020,0003,220Property and equipment, net

    120,237117,82918,972Rental deposits

    38,23638,7336,236Cost method investments

    12,63812,6382,035Intangible assets, net


    51,81951,8198,343Deferred tax assets

    3,0563,041490Accrued interest income

    507719116Total non-current assets

    249,361247,64739,874Total assets1,644,0111,616,939260,344LIABILITIES AND SHAREHOLDERS'
    EQUITYCurrent liabilitiesAccounts payable

    356,095348,76756,155Bills payable

    20,534--Amounts due to related parties

    18,38115,4562,489Accrued expenses and other payables

    105,50397,39515,681Income tax payable

    40,96744,4437,156Deferred income

    14,32714,5682,346Total current liabilities

    555,807520,62983,827Non-current liabilitiesDeferred income

    18,36518,3632,957Deferred tax liabilities

    7,4997,8981,272Other non-current liabilities

    36,23736,9695,952Total non-current liabilities

    62,10163,23010,181Total liabilities617,908583,85994,008Shareholders' equityShare capital

    15815825Additional paid-in capital

    832,811832,811134,091Accumulated other comprehensive loss

    (41,688)(41,825)(6,734)Retained earnings

    234,822241,93638,954Total shareholders' equity

    1,026,1031,033,080166,336Total liabilities and shareholders' equity1,644,0111,616,939260,344

    SOURCE China Nepstar Chain Drugstore Ltd.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. China Nepstar Chain Drugstore Ltd. Announces Appointment of New Director
    2. China Biologic Comments on the Proposed Shanghai RAAS Transaction
    3. Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines
    4. China Pharmaceutical Market Guidebook Series (4) 2013 Report
    5. Hemp, Inc. Signs Letter of Intent with One of Chinas Largest Agricultural Producers, Yasheng Group
    6. RuiYi and Genor BioPharma Collaborate on Development in China of RYI-008, a Novel Therapeutic for Autoimmune Diseases and Cancer
    7. Sinovac Appoints Ernst & Young Hua Ming Llp China as External Auditor
    8. PharmaPoint: Multiple Sclerosis - China Drug Forecast and Market Analysis to 2022
    9. China Jo-Jo Drugstores, Inc. Receives Delisting Notice from NASDAQ
    10. Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China
    11. The World Market for Dialysis Equipment and Services (United States, Japan, UK, Italy, India, China, Australia and Canada )
    Post Your Comments:
    (Date:9/27/2017)...  Commended for their devotion to personalized service, SMP Pharmacy ... one in the South Florida Business Journal,s 50 Fastest-Growing Companies, ... list, the national specialty pharmacy has found its niche.  To ... soon be honored by SFBJ as the 2017 Power Leader ... to receive his award in October, Bardisa said of the ...
    (Date:9/25/2017)...  EpiVax, Inc., a leader in the fields ... announced the launch of EpiVax Oncology Inc., a ... cancer vaccines. EpiVax has provided $500,000 in seed ... technologies to the new precision immunotherapy venture. Gad ... as Chief Executive Officer. Gad brings over 25 ...
    (Date:9/22/2017)... AVACEN Medical (AVACEN) announced that its CE-Marked ... those with the widespread pain associated with fibromyalgia in ... Essex, England commented, "I had ... no sleep at all, tremendous pain, with every movement ... [the AVACEN 100] enough, how this has and is ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The Visiting ... Day Market. Featuring a collection of specialty vendors and unique items from across the ... and quality-focused health and wellness services offered by the VNA. The boutique will ...
    (Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in ... awarded a contract by the Center for Medicare and Medicaid Services (CMS). The ... enterprise use of Agile methodologies in a consistent and high value manner across ...
    (Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the ... today its plans to open a flagship location in Covington, LA at 401 N. ... To Go store next to Office Depot in the Holiday Square shopping center. Its ...
    (Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
    (Date:10/12/2017)... Mich. (PRWEB) , ... October 12, 2017 , ... ... has been named one of Michigan’s 2017 Best and Brightest in Wellness® by ... Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to ...
    Breaking Medicine News(10 mins):